We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CureVac’s Vaccine Candidate Shows Promise in Early-Stage Trial
CureVac’s Vaccine Candidate Shows Promise in Early-Stage Trial
German biopharma company CureVac announced yesterday that its COVID-19 vaccine hopeful generated immune responses and was generally well-tolerated in phase 1 trial participants, lending support for a pivotal trial before year’s end.